Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.

BMC Pulm Med · 2019 · PMC6637533 · PMID 31315668

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

nominally significantp < 0.10so close (0.05 < p ≤ 0.1)

Noting these limitations, these analyses found nominally significant ( p < 0.10) interaction effects for FeNO in both tralokinumab treatment groups and for periostin in the Q4W, but not the Q2W, group (Table 2 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.